Advanced Filters
noise

A, Almada N Clinical Trials

A listing of A, Almada N clinical trials actively recruiting patients volunteers.

Found 10,697 clinical trials
J Jihui Hao, MD

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Objectives of Study:In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

18 years of age All Phase N/A
c carlalberta verna

The Use of a Pacifier to Correct Malocclusions in Young Children

The aim of the study is to investigate the effect of a pacifier (102 Medical Pacifier, Curaprox, Switzerland) on malocclusions like posterior crossbite, anterior open bite, larger overjet and tongue dysfunction in young children.

2 - 5 years of age All Phase N/A
M Michelle Wine Chief Psychologist, Ph.D.

Examining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors

The primary aim of the project is to test the efficacy of BCBT delivered via a digital platform (i.e., smartphone) to Servicemembers with recent suicidal ideation and/or suicide attempts presenting to primary care clinics. Given existing challenges of scaling empirically-supported treatments/interventions for suicidality with fidelity, this project could lead to …

18 years of age All Phase N/A

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, …

12 - 65 years of age All Phase 1
S Shujun Yang, Professor

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

This is a phase I/II study to evaluate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJB001 capsules in patients with advanced solid tumors, including dose escalation phase, dose expansion phase and cohort expansion phase.The study includes screening, treatment and follow-up periods. …

18 years of age All Phase 1/2
K Kar Yee Lor, MBChB

A Comparison of THD® Anopress With High Resolution Anorectal Manometry

Currently, high resolution anorectal manometry (HDARM) is used as gold standard to measure anal sphincter pressures in women who have sustained a third or fourth degree perineal tears (obstetric anal sphincter injuries). This test is performed to help advise patients on future pregnancies or deliveries. However, HDRM catheters are very …

18 years of age Female Phase N/A
T Tao Zhu, professor

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.

18 - 75 years of age All Phase 1
z zhiming Li, Post-doc

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose …

18 - 75 years of age All Phase 1
D David Gradon

Establishing Social Connections in Urban Areas: Evaluating a Community-based Programme

The aim of this study is to evaluate the feasibility and acceptability of a new community-based programme designed to tackle loneliness for young and working-age adults. The programme focuses on encouraging social interactions and connections through offering community initiatives and activities, online spaces for interaction, and free or low-cost social …

20 - 40 years of age All Phase N/A
M Mindy DeMarco

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Evaluate the efficacy safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life (HRQoL) measures in participants with Type I and Type II HAE.

18 years of age All Phase 3

Simplify language using AI